Over the past five years, Zimmer Biomet Holdings (ZBH) has witnessed a dip of 17% in its value. Despite fluctuations, Kevin Thornal leading Global Businesses and the Americas and a buy rating due to growth potential and low valuation suggest a potential upside in the medical devices sector. However, a lower 2025 profit forecast amid tariff uncertainties led the shares to fall. ZBH also announced a Q2 2025 dividend of $0.24, although the earnings have been trending downwards over the last year. Recent notable events include appointment of SVPs, insider selloffs, and acquisition of Paragon 28, aiming to tap into a $5B foot and ankle market. The company's Orthopedic & Musculoskeletal innovation portfolio was highlighted at AAOS 2025, an annual meeting, while its Persona® Revision SoluTion™ Femur received FDA clearance. However, Treace Medical launched legal action against Zimmer Biomet for alleged patent infringement. Despite these uneasy waves, analysts suggest ZBH to be among the best medical device stocks to buy now. The company faces mixed outlook, price target reductions, and software switch impact, but remains a stock to watch.
Zimmer Biomet Holdings ZBH News Analytics from Thu, 05 Sep 2024 07:00:00 GMT to Wed, 25 Jun 2025 12:03:06 GMT -
Rating -3
- Innovation 6
- Information 6
- Rumor -1
